HuiHung MBA - SynCore Biotechnology VP Drugs

All Insiders . Taiwan . 
Stock . SynCore Biotechnology Co . Stakeholders . Insider . HuiHung MBA
4192 Stock  TWD 36.40  0.10  0.28%   

Insider

HuiHung MBA is VP Drugs of SynCore Biotechnology Co
Phone886 3 958 6101
Webhttps://www.syncorebio.com

SynCore Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4348) %, meaning that it generated substantial loss on money invested by shareholders. SynCore Biotechnology's management efficiency ratios could be used to measure how well SynCore Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
SynCore Biotechnology Co has accumulated 61.11 M in total debt with debt to equity ratio (D/E) of 9.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SynCore Biotechnology has a current ratio of 4.94, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist SynCore Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, SynCore Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SynCore Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SynCore to invest in growth at high rates of return. When we think about SynCore Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Victoria LinOBI Pharma
N/A
Kevin PoulosOBI Pharma
64
YuNan ShihOBI Pharma
N/A
Wayne MDOBI Pharma
N/A
ChengEn TsaiOBI Pharma
N/A
Sharon LeeOBI Pharma
N/A
MingTien LaiOBI Pharma
N/A
Mitchell MSOBI Pharma
N/A
ChiChuan ChenOBI Pharma
65
FACP FACPOBI Pharma
67
PoJen ChangOBI Pharma
N/A
ChinChuan ChangAdimmune Corp
N/A
LiYa TangAdimmune Corp
N/A
YinTeng ChangAdimmune Corp
N/A
MBA MDAdimmune Corp
N/A
ChungCheng LiuAdimmune Corp
N/A
Yun YanOBI Pharma
N/A
ChihHsiang LengAdimmune Corp
N/A
Colin KaoOBI Pharma
N/A
ChiHsien ChanAdimmune Corp
N/A
,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people. SynCore Biotechnology Co (4192) is traded on Taiwan OTC Exchange in Taiwan and employs 65 people.

Management Performance

Return On Equity-0.43
Return On Asset-0.16

SynCore Biotechnology Leadership Team

Elected by the shareholders, the SynCore Biotechnology's board of directors comprises two types of representatives: SynCore Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SynCore. The board's role is to monitor SynCore Biotechnology's management team and ensure that shareholders' interests are well served. SynCore Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SynCore Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
ChiaHao Liang, Senior Manager of Finance & Accounting
MuhHwan Su, General Manager
WenHsin Huang, VP Department
FernFang Lin, VP Devel
ChihWen Lee, Chairman of the Board
CharnJung Chang, General Manager-Ophthalmology Project
HuiHung MBA, VP Drugs
RueyWen Lin, Head Department

SynCore Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SynCore Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.43
Return On Asset-0.16
Operating Margin(13.97) %
Current Valuation2.86 B
Shares Outstanding115.08 M
Shares Owned By Insiders66.92 %
Price To Book9.34 X
Price To Sales221.58 X
Revenue6.94 M
Gross Profit2.97 M

Pair Trading with SynCore Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SynCore Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with SynCore Stock

  0.864743 Oneness BiotechPairCorr
  0.896547 Medigen Vaccine BiologicsPairCorr
  0.834174 OBI PharmaPairCorr

Moving against SynCore Stock

  0.872882B Cathay Financial HoldingPairCorr
  0.872891 CTBC Financial HoldingPairCorr
  0.862891B CTBC Financial HoldingPairCorr
  0.842881A Fubon Financial HoldingPairCorr
  0.752881B Fubon Financial HoldingPairCorr
The ability to find closely correlated positions to SynCore Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SynCore Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SynCore Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SynCore Biotechnology Co to buy it.
The correlation of SynCore Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SynCore Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SynCore Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SynCore Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for SynCore Stock Analysis

When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY